Atlas Wealth’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Atlas Wealth’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36K	Hold	19,620	–	–	﹤0.01%	177
2026 Q1	$999	Buy	+19,620	New	+$999	﹤0.01%	115
2025 Q4	–	Sell	-26,620	Closed	-$2.37K	–	116
2025 Q3	$2.37K	Hold	26,620	–	–	﹤0.01%	107
2025 Q2	$1.92K	Hold	26,620	–	–	﹤0.01%	108
2025 Q1	$2.66K	Hold	26,620	–	–	﹤0.01%	97
2024 Q4	$3.2K	Hold	26,620	–	–	﹤0.01%	94
2024 Q3	$2.61K	Sell	26,620 -26,620	-50%	-$2.61K	﹤0.01%	82
2024 Q2	$6.78K	Buy	53,240 +26,620	+100%	+$3.39K	﹤0.01%	234
2024 Q1	$4.87K	Hold	26,620	–	–	﹤0.01%	78
2023 Q4	$2.25K	Hold	26,620	–	–	﹤0.01%	78
2023 Q3	$2.25K	Hold	26,620	–	–	﹤0.01%	221
2023 Q2	$3.06K	Hold	26,620	–	–	﹤0.01%	229
2023 Q1	$4.39K	Hold	26,620	–	–	﹤0.01%	229
2022 Q4	$2.88K	Buy	+26,620	New	+$2.88K	﹤0.01%	128

Other funds holding PVCT

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Financial Symmetry Raleigh, North Carolina $300M AUM 23.79% 1-Year Est. Return

Atlas Wealth's PVCT Position: Q2 2026 in Review

Atlas Wealth held its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) position steady in Q2 2026 at 19,620 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #177.

Atlas Wealth first reported a position in PVCT in Q4 2022 and has held it in 14 quarters since. The position peaked at $6.78K in Q2 2024. 3 funds tracked by Wall St. Rank hold PVCT as of Q2 2026.

Atlas Wealth held 19,620 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $1.36K as of Q2 2026.
Atlas Wealth left its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) share count unchanged in Q2 2026.
PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up ﹤0.01% of Atlas Wealth's portfolio in Q2 2026, its #177 holding.
Atlas Wealth first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2022 and has held it in 14 quarters since.
Atlas Wealth's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $6.78K in Q2 2024.
3 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2026.

Based on Atlas Wealth's 13F filing for Q2 2026, filed 28 Jul 2026.